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Abstract 
 
Post-translational modifications play an essential role in regulating protein 
structure and function. Enzymes catalyzing these modifications must often 
recognize and modify multiple substrate proteins from among a plethora of non-
substrates with similar structures and amino acid sequences. For example, protein 
farnesyltransferase (FTase) catalyzes the addition of an isoprenoid group to a 
cysteine near the C-terminus of a substrate protein and is proposed to modify a 
pool of substrates numbering more than one hundred. We seek to understand the 
interactions in the FTase active site that engender substrate selectivity. By 
mutating two residues within FTase, we have developed FTase variants with 
expanded substrate selectivity. The alteration in substrate selectivity observed in 
our variants suggests that FTase selectivity may depend on a small number of 
“tunable” active site contacts. Our work provides insight into how this 
multispecific enzyme recognizes its pool of substrates and will also aid in 
identifying additional FTase substrates.  
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5 
Introduction 
 
 Protein prenylation is an important posttranslational modification required for 
the proper localization and function of many eukaryotic proteins (6). Prenylated 
proteins are involved in vital cell signaling transduction pathways that control cell 
growth and differentiation, with these proteins linked to diseases including cancer 
and cardiovascular disease (10). Understanding how protein prenylation affects 
cellular health requires us to identify which proteins are prenylated and then 
characterize the impact of prenylation pathwaymodifications on protein structure 
and function. 
 Protein farnesyltransferase (FTase) is a heterodimeric enzyme that catalyzes the 
addition of a fifteen-carbon prenyl group to the cysteine of the “Ca1a2X” C-
terminal sequence of a substrate protein, 
the first step in the prenylation pathway 
(Figure 1). This prenyl group increases 
the hydrophobicity of the protein and 
aids in localizing the peptide to cellular 
membranes (1)  FTase readily 
prenylates a range of Ca1a2X sequences, 
but the interactions that lead to 
selectivity within the Ca1a2X sequence 
are still not well defined (2-5, 11). A 
2009 study by Hougland and coworkers Fig 1. Prenylation pathway 
 suggests that the hydrophobicity and steric volume of the a
determinants of peptide selectivity by 
FTase (6).   
 In addition to understanding what 
properties within the protein substrate 
are recognized by FTase, we must also 
identify the amino acids within the 
FTase active site that transduce these 
interactions involved in substrate 
selectivity.  Both structural and 
biochemical studies indicate that t
W102β and W106β
recognizing the a2 
also been demonstrated to alter FTase 
“tunable” nature of substrate selectivity in FTase 
 To explore more fully the potential for altering FTase substrate selectivity 
through mutation of two active site residues, 
FTase variants using a previously generated FTase plasmid library wherein the 
codons for the two active 
randomized. A subset 
three target peptides,
are markedly less reactive 
GCVLS).  Using a fluorescence
2 residue serve as 
he 
 residues within the active site of FTase play the key roles in 
residue (Figure 2) (2, 7). Mutation of these two residues has 
substrate selectivity, thereby revealing the 
(7).  
we developed a library of ~400
site amino acids,  W102β and W106β, have been 
of these variants were screened for prenylation activity with 
 CVDS, CVYS, and CVGS, that bear Ca1a2X sequences that 
with FTase than “natural” substrates such as 
-based assay that probes prenyltransferase activity 
Fig 2. Interaction of a2 with the W102
(orange) and W106β (red) residues of 
wildtype FTase. The lipid tail of a FPP 
analogue (purple) is also shown here to 
contact the a2 residue. Fi
 
6 
 
H-Ras  (-
β 
gure from ref 6. 
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in bacterial cell lysates, we isolated two variant FTases from among the screened 
variants that exhibited prenylation activity with the CVYS target peptide. These 
two variants were then expressed, purified, and their enzymatic activity 
characterized under steady state conditions. Unexpectedly, we also observed and 
characterized the resistance of these two variants to the highly selective and 
potent FTase inhibitor, FPTII.  
 These studies provide a deeper understanding of the interactions that engender 
a2 selectivity in FTase and promote the development of FTase variants that will 
serve as tools for studying prenylation pathway modifications within the cell. In 
addition, the characterization of FTase substrate recognition derived from my 
research will also provide insight for the development of better FTase inhibitors, 
an active area of drug research that is currently hindered in part because the 
specific protein targets of FTase are unknown (8, 12). 
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MATERIALS AND METHODS 
 Preparation of W102β and W106β FTase variant library. A previously 
generated variant FTase plasmid library with mutations at W102β and W106β in 
the context of the pET23aPFT vector was utilized to generate the FTase variant 
libraries described herein (7).  Codons for positions 102β and 106β have been 
randomized using an NNK codon (N = equal mixture of A, T, C, and G, K = G or 
T). To generate a library of FTase variants, 24 ng (3 µL of 8 ng/µL) of the variant 
FTase plasmid DNA was transformed into each of four 100 µL aliquots of Z-
competent BL21(DE3) E. coli cells (73.4 ng/µL). A plasmid for wild-type FTase 
(21.4 ng) was also transformed into a 100 uL aliquot of Z-competent BL21(DE3) 
E. coli cells. The cells were plated onto LB agar plates containing 100 µg/mL 
ampicillin and grown overnight (~ 16 hours).  
 Following overnight incubation, 376 single colonies were inoculated into single 
wells of four 96-well (2.2 mL well volume) growth plates using sterile toothpicks. 
Each well contained 900 µL of filter sterilized (0.22 µm) growth media composed 
of LB media, 1% glucose, 100 µg/mL ampicillin and 60 µM isopropyl β-D-1-
thiogalactopyranoside (IPTG). Each of the four 96-well plates contained a well 
inoculated with one colony transformed with wild-type FTase to serve as a 
positive control, a well inoculated with one colony transformed with an empty 
pET23a vector to serve as a negative control, and 94 wells inoculated with 
colonies transformed with variants.  The four plates were labeled Cultures 1 – 4, 
sealed with gas-permeable adhesive seals, and incubated with shaking (400 RPM) 
for 16 hours at 28°C.  Following incubation, cultures 2- 4 were sealed and stored 
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at -80°C. Glycerol stocks for variants in the Culture 1 plate were prepared by 
aliquoting 50 µL of culture from each well into another growth plate with 450 µL 
of LB with 100 µg/mL ampicillin in each well. Following incubation with shaking 
(400 RPM) for 16 hours at 28°C, the cultures in each well was mixed with 500 µL 
of 20% sterile glycerol. The resulting glycerol stock was stored at -80°C. 
 Screening of FTase variants. Cultures in each well of the Culture 1 plate were 
lysed using 100 µL of cell lysis reagent per well. The cell lysis reagent consists of 
9.6 mL Fast Break cell lysis reagent (Promega), 4.8 µL benzonase (125 U/mL), 1 
mL lysozyme (20 mg/mL in purified water) and 384 µL 
phenylmethanesulfunylfluoride (PMSF, 5 mg/mL in ethanol), with PMSF added 
last. Following addition of 100 µL of cell lysis reagent per well to the  Culture 1 
plate, the plate was shaken (380 rpm) for 20 minutes at 28°Cand then stored on 
ice until used in screening assays. 
 A steady-state kinetics fluorescence assay was used to screen for FTase variants 
capable of farnesylating selected dansylated peptides. Farnesylation of dansylated 
peptides was monitored by fluorescence using a POLARstar Galaxy plate reader 
(λex 340 nm, λem 520 nm) for 4 hours. Farnesylation of the dansylated peptides 
leads to an increase in fluorescence of the dansyl fluorophore, (9) providing a 
signal for peptide prenylation. Screening reactions for FTase variant activity with 
target peptides were as follows, with reactions run at room temperature: 3 µM 
dansylated peptide, 5 µL cell lysate, 10 µM farnesyl pyrophosphate (FPP), 50 
mM HEPPSO pH 7.8, 5 mM tris(2-carboxyethyl)phosphine (TCEP), and 5 mM 
MgCl2. 
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 Recent studies of in vivo protein prenylation in the Hougland Lab have 
identified a set of peptide sequences with point mutations at the a2 residue that 
appear to block prenylation by wild type FTase (S. Flynn, manuscript in 
preparation). From among these sequences, CVDS, CVYS, and CVGS were 
selected as initial targets for FTase variant selection. In addition to these three 
target peptides, FTase variant activity reactions were run in parallel with the 
“natural” substrate CVLS to determine if the FTase variants retain activity with a 
positive control substrate.   
 For each screening reaction, a 96 well reaction plate was prepared for each 
peptide substrate as follows; a typical set of screening reactions involved four  96 
well plates. A reaction stock solution was prepared, consisting of 11.9 mL dH20, 2 
mL of 10x reaction buffer (500 mM Heppso pH 7.8, 50 mM TCEP), 100 µL 5 
mM MgCl2, and 4 mL 10 µM FPP. The stock solution (45 µL) was aliquoted into 
each well of the 96 well reaction plates. Cell lysate (5 µL) from each well of the 
Culture 1 growth plates was transferred into its corresponding well in each of the 
four reaction plates (lysate from well A01 was added to well A01 of reaction 
plates 1,2,3 and 4, lysate from well A02 was added to well A02 of reaction plates 
1,2,3 and 4, etc.) Reactions were initiated by the addition of 50 µL of a 6 µM 
peptide stock into each well. Each reaction plate was initiated by a different 
peptide (reaction plate 1 with dansyl- GCVLS, reaction plate 2 with dansyl-
GCVYS, etc.)   
 Fluorescence was measured at 12 time points (0 min, 10 min, 20 min, 30 min, 
40 min, 50 min, 60 min, 90 min, 120 min, 150 min, 180 min and 240 min). The 
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results were combined to determine the time dependence of the fluorescence 
change for each variant with each peptide.  Reactions whose variants who both 
exhibited a minimum fluorescence change that is at least 70% of the maximum 
change of wild-type FTase with dansyl-GCVLS (~2450 Au) and reached 
completion (a plateau in fluorescence) within 2-fold of the time required for wild-
type FTase with dansyl-GCVLS (~100 min) were considered active. Two active 
variant FTases exhibiting prenylation activity with the CVYS target peptide 
(Wells A05 and F03) were selected from this screen, sequenced, and purified. 
Sequencing of Selected FTase Variants: The BL21(DE3) E. coli cells 
containing the plasmids for the two selected variants were regrown from the 
glycerol stock. For each variant, a minimal amount of frozen culture was 
inoculated into a culture tube containing 5 mL 2xYT media supplemented with 
2% glucose and 100 µg/mL ampicillin. The cells were incubated with shaking 
(275 rpm) for 16 hours at 37°C.  Following overnight culture, the plasmid 
encoding the FTase variant was purified using the protocol for purification of low 
copy plasmid DNA from the EZ-10 Spin Column Plasmid DNA MiniPrep Kit 
(Bio Basic Inc). Plasmid concentrations were determined by UV-Vis spectroscopy 
using the Nanodrop 2000c UV-Vis spectrometer, and the mutations at positions 
102 and 106 were determined by DNA sequencing (Genewiz).   
Purification of Selected FTase Variants. For each FTase variant, 1 µL of 
plasmid (30.7 ng/µL for A05 and 92.7 ng/µL for F03) was transformed into a 100 
uL aliquot of BL21-DE3 E. coli cells and plated on a LB agar plate containing 
100 µg/mL ampicillin. Following overnight incubation, a single colony was 
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inoculated into 5 mL 2xYT growth media with 100 µg/mL ampicillin and 
incubated with shaking (225 rpm) at 37°C. After 5 hours incubation, the 5 mL 
starter culture was inoculated into a 3 L baffled flask containing 1 L of sterile 
autoinduction media (10 g tryptone, 5 g yeast extract, 872.5 mL of H2O (pH 
adjusted to 7.45 with KOH), 25 mL 1M Na2HPO4, 25 mL 1M KH2PO4, 50 mL 
1M NH4Cl, 5 mL 1M Na2SO4, 2 mL 1M MgSO4, 200 µL trace metals) with 100 
µg/mL ampicillin and incubated with shaking (200 rpm) for 24 hours at 28°C.  
Following incubation, cells were harvested by centrifugation (6000 rpm, 15 
min, 4°C) and the pellet was re-suspended in 50 mL resuspension buffer (50 mM 
HEPES pH 7.8, 10 µM ZnCl2, 2 mM TCEP, 17 µg/mL PMSF).  Prior to lysis, 
benzonase (7.875 µL/63mL), lysozyme (0.2 mg/mL) and PMSF (17 µg/mL) were 
added to the cell suspension. After a 45 min. incubation period at 37°C, the cells 
were lysed by sonication (8 x 30 seconds at 30 Watts, with 30 second rests 
between cycles). Following sonication, cell debris was removed by centrifugation 
(18000 x g, 45 min, 4°C).  The supernatant was treated with 1/10 volume of 10% 
streptomycin sulfate added drop wise in the cold room followed by stirring for 20 
min at 4°C.  The resulting solution was clarified by centrifugation (18000 x g, 45 
min, 4°C), followed by filtration through a 0.45 µM syringe filter.  
The filtered supernatant was loaded onto a HiTrap DEAE anion-exchange 
column (3 x 5mL prepacked columns) washed with HTZ buffer (50 mL 1 M 
Hepes pH 7.8, 4 mL 2.5 mM ZnCl2, 946 mL H2O and 0.6 g TCEP) and FTase was 
eluted by a NaCl gradient (HTZ + 0.5 M NaCl buffer) per preprogrammed 
gradient (AktaPrime, GE Healthsciences). Fractions containing FTase were 
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determined by SDS-PAGE analysis, collected, concentrated with 30K 
concentrators (PALL MacroSep Advance Centrifugal Devices), and diluted to 10 
mL with HZ buffer (HTZ buffer without TCEP). The partially purified FTase was 
likewise purified using a HiTrapQ anion-exchange column (3 x 5mL prepacked 
columns) using a NaCl gradient, concentrated to ~10 µM as determined by UV 
absorbance at 280 nm (extinction coefficient 1.5 x 105 M-1cm-1) and stored in 25 
uL aliquots at -80°C.  
Active Site Titration of purified FTase Variants: The concentration of active 
enzyme was determined by active site titration of the purified variants.  . 
Increasing concentrations (between 0 nM to 1000 nM) of the dansyl- CVLS and 
dansyl - CVYS peptides were titrated into 100 µL solutions containing 300 nM 
enzyme, 5 µM FPTII inhibitor, 1x FTase reaction buffer (50 mM Heppso pH 7.8, 
5 mM TCEP) and 5 mM MgCl2. After the addition of peptide, the sample was 
incubated in the dark for 10 minutes to allow peptide binding to reach completion 
before a fluorescence (λex 280 nm, λem 496 nm) reading was obtained. Reactions 
lacking enzyme were run in parallel as negative controls. The concentration of 
enzyme active sites was calculated from the collected data by finding the 
intersection of the linear slope lines for pre-saturated and saturated conditions of 
the FTase-FPTII complex by dansylated peptide.  
Steady-State Kinetics of Variant Enzymes. To measure the effects of the 
mutations on the catalytic efficiency (kcat/KM) of FTase, the velocity for peptide 
farnesylation at multiple peptide concentrations was determined using the 
previously reported fluorescence-based assay (9). Increasing concentrations  of 
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dansyl- CVLS and dansyl - CVYS peptide (0.2 µM, 0.5 µM, 1 µM, 2 µM, 5 µM 
and 10 µM) were titrated into 100 µL solutions containing 20 nM enzyme, 10 µM 
FPP, 1x FTase reaction buffer and 5 mM MgCl2. Immediately after reaction 
initiation by the addition of the enzyme stock, fluorescence was measured as a 
function of time for 4 hours. KM was determined from Lineweaver-Burk plots; a 
linear fit to the dependence of the inverse substrate concentration on inverse 
initial velocity (eq 1). Initial velocity (V, µM/s) was determined by dividing the 
linear velocity of the reaction in fluorescence units per second by an amplitude 
conversion derived from an average of the total fluorescence change observed 
upon reaction completion divided by the initial peptide substrate concentration. 
kcat was derived from equation 2, where [E0] = enzyme concentration.  
  1/ = (KM/Vmax)(1/[s]) + 1/Vmax  (1) 
  Vmax = kcat[E0]     (2) 
Testing of FPTII Inhibitor Resistance. To determine the effects of the 
mutations on the affinity of FPTII inhibitor with FTase, increasing concentrations 
of FPTII inhibitor (0 µM, 0.1 µM, 1.0 µM and 10 µM) were titrated into solutions 
with 20 nM enzyme, 2 µM peptide, 1x FTase reaction buffer, 5 mM MgCl2 and 
10 µM FPP. The velocity for peptide farnesylation in the presence of FPTII 
concentrations was determined using the previously reported fluorescence-based 
assay (9). The dissociation constant Ki of FPTII was determined from a fit of the 
Michaelis-Menten equation adjusted for inhibition (eq 3) to the dependence of 
initial velocity on FPTII concentration. 
  V=V0 * (1  
	

)    (3) 
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KM values for FPP with the selected variants were also measured using the 
fluorescence-based assay. Increasing concentrations of FPP (0.1 µM, 0.5 µM, 1 
µM, 2 µM, 5 µM and 10 µM) were titrated into solutions with 15 nM enzyme, 2 
µM dansyl-CVLS, 1x FTase reaction buffer and 5 mM MgCl2. Fluorescence (λex 
340 nm, λem 520 nm) was monitored for four hours, and initial velocities were 
measured as described above. KM of FPP was determined from a fit of the 
Michaelis-Menten equation (eq 4) to the dependence of initial velocity on the FPP 
concentration.  
  V=Vmax ( 


)    (4) 
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Mutagenesis of pCAF2 vectors. The shuttle vector pCAF was previously 
modified to allow for co-expression of FTase and a florescent fusion protein (7). 
In the vector pCAF2 WW CVLS (Figure 3), wild-type FTase was cloned into 
open reading frame 1 (ORF1) and TagRFP-GCVLS into open reading frame 2 
(ORF2). ORF1 is under the control of the CMV promoter while ORF2 is under 
the control of the SV40 promoter. FTase variants were first introduced into the 
pCAF2 WW CVLS plasmid by PCR site-directed mutagenesis. Mutations were 
confirmed by DNA sequencing (GENEWIZ) using the CMV forward primer. The 
TagRFP-CVYS mutation was then introduced into the pCAF variant CVLS 
template and confirmed by sequencing using the SV40 reverse primer.  
Cell culture, transfection, and imaging. HEK293T cells were cultured 
in DMEM (Invitrogen) supplemented with 100 units/mL penicillin-streptomycin 
Fig. 3: pCAF2 WW CVLS Vector 
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and L-glutamine (2mM) and 10% fetal bovine serum (Complete Media). Cells 
were maintained in a humidified atmosphere with 5% CO2 at 370C.  HEK 293T 
cells (4 x 104 cells) were plated in a 24 -well tissue culture treated plate (2.0 cm2 
well size) and incubated for 24 and 48 hours. Cells were then transfected with 3µg 
plasmid DNA using TurboFect (Fermenta) according to manufacturer’s protocols. 
Following transfection for 48 hours, the cells were imaged using 
a Zeiss Axio Vert A1 fluorescence microscope, with a minimum of 50 cells were 
characterized and reported. 
RESULTS 
 Selection of W102β and W106β mutants with increased reactivity with dansyl – 
GCVYS. In the screening of novel FTase variants, 376 E. coli colonies derived 
from the FTase plasmid library with double mutations at W102β and W106β were 
selected to be assayed for farnesylation activity with peptide targets. Of the 94 
variants screened, 31% (29/94 variants) exhibited high prenylation activity with 
dansyl–GCVLS while 43% (40/94 variants) exhibited high prenylation activity 
with dansyl –GCVYS. A variants is defined as exhibiting “high prenylation 
activity” if the prenylation reaction with the target peptide satisfies two criteria: 1) 
reaction completion within 2-fold of the time required for wildtype - FTase to 
reach completion with its native substrate dansyl-GCVLS (~100min); and 2) a 
minimum fluorescence change at least 70% of the maximum fluorescence change 
observed for wildtype-FTase with dansyl-GCVLS (~2450 Au). The large pool of 
variants that were able to prenylate the non-native substrate CVYS suggests that 
substrate selectivity in FTase is easily altered and depends fundamentally on a 
 small number of “tunable” active site contacts
(7). 
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Selected FTase variants Two variant FTases that exhibited high prenylation 
activity with the CVYS target peptide as well as the native CVLS peptide (Figure 
4) were isolated; these variants were sequenced and the mutations at W102β and 
W106β are reported in Table 1. The kcat/KM values for these variants for reaction 
with both the dansyl- CVLS and dansyl–CVYS peptides were calculated from 
Lineweaver-Burk plots (Figure 5 and Table 2). Both the W102F W102L and 
W102Y W106L mutants exhibit a ~100-fold increase in dansyl-GCVYS activity 
when compared with wildtype-FTase. The mutants also simultaneously maintain 
approximately the same level of activity 
(within 2-fold) with dansyl-GCVLS as wildtype-FTase. These findings are 
consistent with our earlier observations that the FTase active site is flexible and 
that substrate selectivity can be easily modulated.  
 
 
Well Residue at position 
102 
Residue at position 
106 
WW FTase     W      W 
A5 
    Y      L 
F3 
    F      L 
Enzyme Kcat/KM (M-1s-1)  
LS 
Kcat/KM (M-1s-1)  
YS 
WW FTase 11.7 x 105 ± 40 12.1 x 103 ± 200 
YL Variant 9.8 x 104 1.2 x 105 
FL Variant 9.6 x 104 1.3 X 105 
Table 1. Residues at position 102β and position 106β of wildtype and 
selected variant FTases. 
Table 2. The K
cat/KM values of wildtype FTase and the two variants (YL, FL) 
with the peptides –GCCVLS and –GCVYS.   
  
Variant Resistance to FPTII Inhibitor
purified WT FTase
point indicative of peptide binding saturation while
do not.   This lack of saturation 
interfere with formation of the initial FTase*FPTII complex or the formation of 
the FTase*FPTII*peptide c
affected in the YL
FPTII inhibitor was measured with each variant with either dansyl
dansyl-GCVYS peptide substrates
Fig 5.  A Lineweaver
plot fits a linear model corresponding to the inverse of the Michaelis
equation  from which the K
run with 20 nM enzyme. 
. During the active site titrations of 
 and FTase variants, wildtype-FTase reaches a clear saturation 
 the FL and YL FTase 
suggests that the FL and YL active site mutations 
omplex.  To determine if FPTII inhibitor binding is 
 and FL FTase variants, the inhibition constant 
. Results are shown in Table 3. 
-Burk plot of the FL variant with dansyl-GCVYS. The 
cat/KM value can be calculated. This reaction was 
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the 
variants 
(Ki) for the 
-GCVLS or 
The increased 
-Menten 
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Ki values of FPTII with the variants and the dansyl-CVLS substrate as compared 
to wildtype-FTase suggest a decreased affinity of FPTII inhibitor for FTase, 
which is consistent with our results. The Ki of FPTII of the FL variant with CVYS 
is considerably lower than the Ki of FPTII of the FL variant with CVLS. This 
suggests that inhibitor resistance maybe substrate dependent.  
 
The increased resistance to the competitive inhibitor FPTII in the presence of a 
saturating amount of FPP suggests either a decrease in the binding affinity of 
FPTII and/or an increase in the binding affinity of FPP.  The values of KM of FPP 
with the variants, calculated from FPP titrations, are reported in Table 4. The 
decreased KM of FPP with the variants as compared to wildtype-FTase is 
consistent with the variants exhibiting tighter FPP binding, which could lead to 
less effective competitive inhibitor by FPTII. 
 
 
 
 
Table 3. Ki values of FPTII inhibitor with wildtype FTase, FL FTase and YL 
FTase with the peptides dansyl-CVLS and dansyl-CVYS 
Enzyme Ki (uM) 
LS 
Ki (uM)  
YS 
WW FTase 0.3 ± 0.2 NA 
YL Variant 5.1 ± 5.3 NA 
FL Variant 13.5 ± 15.6 0.23 ± 0.042 
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Reactivity of Selected Variants in vivo. To examine farnesylation activity of the 
W102F W106L and W102Y W106L variants in vivo, pCAF2 vectors containing 
the mutants were transfected into HEK293T cells. The pCAF2 vectors  
allowed for co-expression of a variant FTase along with a fusion protein tagged 
with a red fluorescent protein (TagRFP) at its N-terminal. The fusion protein 
comprises of the upstream sequence H-Ras (-KLNPPDESGPGCMSC-) and either 
–GCVLS or GCVYS at its C-terminal. Farnesylation activity was monitored by 
the localization of the fusion protein as determined from the distribution of 
fluorescence.  
The cells were characterized as “Localized” where the reporter protein is 
located mainly to the plasma membrane, “Mixed” where the reporter protein 
located at cellular membranes and throughout the cytosol and “Diffuse” where the 
reporter protein is located throughout the cytosol (Figure 6). In the vector with 
wildtype FTase and TagRFP-CVLS, 50% of the cells exhibit localized 
fluorescence and 50% display mixed fluorescence. Changing the C-terminal 
sequence of the fluorescent protein to CVYS in the presence of wild-type FTase 
(WW CVYS) leads to a complete loss of “localized” fluorescence, with 97% of 
Enzyme KM (M) 
LS 
WW FTase 7.56 ± 3.0 
YL Variant 0.92  ± 0.37 
FL Variant 1.0 ± 0.17 
Table 4. The KM values of FPP with wildtype FTase, W102F W106L FTase and 
W102Y W106L FTase with dansyl-CVLS  
 cells exhibiting diffuse 
the FL FTase variant 
cells displaying mixed f
(Figure 7).  These results indicate that the FL FTase variant is active within the 
cell.  
 
 
A 
Fig 6. Examples of TagRFP fluorescence localization in HEK293T cells: 
B. Mixed C. Localized
Fig 7. Fluorescent Localization of pCAF2 XX 
fluorescence and 3% mixed fluorescence. 
in the presence of TagRFP-CVYS increased the number of 
luorescence, but did not lead to localized fluorescence 
C B 
 
CVa2S in HEK293T cells. 
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DISCUSSION 
The W102β and W106β residues of FTase play the key roles in recognizing the 
a2 residue, one of the determinants of peptide selectivity by FTase. The two 
developed FTase variants, W102F W102L and W102Y W106L, exhibit 
farnesylation activity with the CVLS and CVYS peptide. The chosen target 
peptide, CVYS, differs from the native substrate CVLS in that the amino acid at 
its a2 position is larger while remaining hydrophobic. The two FTase variants 
selected in this work for their increased reactivity with the CVYS peptide both 
contain a tryptophan to leucine mutation at position 106β, which maintains 
hydrophobic character at this position while reducing amino acid size. Mutations 
observed at position 102β keep an aromatic amino acid at this position while also 
reducing amino acid size. These mutations suggest that increasing reactivity with 
the CVYS peptide requires relaxation of steric discrimination within the FTase 
active site pocket while preserving hydrophobic character in the a2 binding 
pocket. The change in substrate selectivity observed in this work demonstrates the 
flexibility of the FTase active site and suggests that FTase selectivity is easily 
tunable with directed mutations at the W102β and W106β residues. 
Notably, the FTase variants are capable of accelerating reactions with the –
GCVYS peptide ~100 fold without losing reactivity with –GCVLS. This 
conservation of activity with GCVLS with W102β and W106β mutants has been 
observed in previous studies (7). The reactivity of the W102F W102L and 
W102Y W106L variants with CVLS reconfirm that the W102β and W106β 
residues are not vital in selecting for the natural substrate for prenylation. Instead, 
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the residues at the 102β and 106β positions select against substrates on the basis 
of size and polarity (7).  
Bioengineered prenylation pathway. By mutating two residues within FTase, 
FTase variants with expanded substrate selectivity were developed. Studies of the 
enzymes involved in latter steps of the prenylation pathway have been restricted 
by the limited substrates of FTase. The novel variants identified in this study that 
can prenylate substrates with the CVYS as well as the CVLS motif lessens this 
constraint and can serve as tools for future prenylation studies.  
 In addition, studies of any single prenylation pathway within a cell have been 
limited because isolation of a single pathway was not possible; inhibitor treatment 
of FTase or any succeeding enzyme knockouts every farnesylation pathway 
within the cell. The unexpected finding that the novel variants are resistant to the 
inhibitor FPTII makes them all the more powerful as tools as they potentially can 
be implemented in a single specific prenylation pathway in in-vivo studies without 
the background of other prenylation pathways.  
 In conclusion, the W102β and W106β residues of FTase are easily tunable for 
controlled substrate selectivity. Variant FTases/fusion protein pairs are also 
powerful tools for studying prenylation modifications downstream of FTase 
farnesylation. This will ultimately lead to a better understanding of the 
prenylation pathway inhibitors effective against prenylate Ras-protein diseases 
such as cancer and cardiovascular disease.  
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Capstone Summary 
 Posttranslational modification, a critical step in protein biosynthesis, plays 
an essential role in regulating protein structure and function. Within a cell, 
posttranslational modifications are carried out by enzymes, catalytic biological 
molecules that accelerate the rate of chemical reactions. Protein prenylation is an 
important posttranslational modification required for the proper localization and 
function of many eukaryotic proteins. In the first step of the prenylation pathway, 
the enzyme farnesyltransferase (FTase) catalyzes the addition of a fifteen-carbon 
prenyl group to the cysteine of the “Ca1a2X” C-terminal sequence of a substrate 
protein. However, the interactions that lead to selectivity within the Ca1a2X 
sequence are still not well defined and FTase is proposed to modify a pool of 
substrates numbering more than one hundred.  
  Prenylated proteins are involved in vital cell signaling transduction 
pathways that control cell growth and differentiation, with these proteins linked to 
diseases including cancer and cardiovascular disease. Understanding how protein 
prenylation affects cellular health requires us to identify which proteins are 
prenylated and then characterize the impact of prenylation pathways 
modifications on protein structure and function. We seek to understand the 
interactions in the FTase active site that engender substrate selectivity.  
  In this study, we developed a library of ~400 FTase variants using a 
previously generated FTase plasmid library wherein the codons for the two active 
site amino acids, W102β and W106β, have been randomized. Codons, specific 
sequences of three nucleotides, determine the amino acid that is translated into the 
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peptide; thus, randomized codons at position W102β and W106β will result in 
random amino acids at those positions. 94 of the variants were screened for 
prenylation activity with three target peptides that bear Ca1a2X sequences that are 
less reactive than native FTase substrates such as Ras (-CVLS) in parallel to the 
natural substrate CVLS serving as a positive control. The peptide substrates were 
labeled with a dansyl group to allow monitoring of peptide prenylation activity by 
changes in dansyl fluorescence.  
  Two variant FTases that exhibited prenylation activity with the CVYS 
target peptide were isolated from this screen. The mutated vectors were sequenced 
and subsequently isolated and transformed into a strain of E. coli cells that is able 
to express the FTase protein. The protein was purified by ion exchange Fast 
Protein Liquid Chromatography (FPLC), a technique used to separate proteins by 
charge.  
  Following purification, we characterized their reactivity with the 
associated peptide targets to investigate how the mutations we observe lead to 
changes in substrate selectivity. This included measuring peptide substrate 
binding affinities, reaction velocities in the presence of both saturating and 
subsaturating peptide concentrations, and the maximum rate for substrate turnover 
by the selected FTase variants. We also tested the variants’ resistance to the 
highly selective and potent inhibitor of wildtype FTase, FPTII.  
  In addition, to determine if the selected FTase variants exhibit biologically 
relevant levels of prenylation activity, we assessed the ability of these variants to 
prenylate a target fluorescent protein within a mammalian cell. Prenylation of the 
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target protein leads to protein localization to cellular membranes, which can be 
monitored by fluorescence microscopy.  By co-expressing the given FTase variant 
with a fluorescent protein terminating the peptide sequence used to select the 
FTase variant, we determine if each variant is active enough to prenylate the 
target protein leading to a change from diffused to localized fluorescence. 
  These studies will ultimately lead to a better understanding of the 
selectivities and substrates for wildtype FTase. By mutating two residues within 
FTase, we have developed FTase variants with expanded substrate selectivity. 
The alteration in substrate selectivity observed in our variants suggests that FTase 
selectivity may depend on a small number of “tunable” active site contacts. Our 
work provides insight into how this multispecific enzyme recognizes its pool of 
substrates and will also aid in identifying additional FTase substrates. Studies of 
the enzymes involved in latter steps of the prenylation pathway have been 
restricted by the limited substrates of FTase. The novel variants identified in this 
study that can prenylated substrates with the CVYS as well as the CVLS motif 
lessens this constraint and can serve as tools for future prenylation studies. The 
unexpected finding that the novel variants are also resistant to the inhibitor FPTII 
makes them all the more powerful as tools as they can be implemented in a single 
specific prenylation pathway in in vivo studies without the background of other 
prenylation pathways.  
  In addition, the characterization of FTase substrate recognition derived 
from my research will provide insight for the development of better FTase 
inhibitors, an active area of drug research that is currently hindered because the 
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specific protein targets of FTase are unknown. FTase inhibitors have been 
designed and have been proven effective in the treatment of prenylated Ras-
protein-related diseases such as various forms of cancer by suppressing 
angiogenesis and inducing apoptosis.  
 
 
